Prenetics' IM8 Closes $1B Non-Dilutive Growth Financing from General Catalyst
PRE has more than doubled off its 52-week low of $7.175.
Summary
Prenetics' IM8 brand closed a $1 billion non-dilutive growth financing facility from General Catalyst's Customer Value Fund. The facility funds up to 70% of IM8's marketing spend, with repayment tied solely to revenue from funded customer cohorts—no equity, warrants, or fixed repayment obligations. This follows a series of strategic moves including a $40M Bitcoin divestiture, a partnership with Inter Miami CF, and a $40M share buyback program. The structure allows IM8 to aggressively scale customer acquisition across 43 markets without straining Prenetics' $139.7M cash position. Every IM8 cohort has exceeded performance thresholds, and the AI-driven acquisition engine compounds efficiency as data accumulates. The deal removes a key growth constraint and preserves balance sheet strength for product innovation and strategic opportunities.
At the time of this announcement, PRE was trading at $20.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $343.8M. The 52-week trading range was $7.18 to $23.63. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.